多囊卵巢
益生菌
不育
子宫内膜异位症
心理干预
病因学
医学
妇科
微生物群
重症监护医学
生物信息学
生物
内科学
肥胖
胰岛素抵抗
怀孕
细菌
精神科
遗传学
作者
Alessia Favaron,Engin Türkgeldi,Moe Elbadawi,Simon Gaisford,Abdul W. Basit,Mine Orlu
标识
DOI:10.1016/j.rbmo.2023.103734
摘要
Disruption of women's gut and cervicovaginal microbiota has been associated with multiple gynaecological diseases such as endometriosis, polycystic ovary syndrome, non-cyclic pelvic pain and infertility. Female infertility affects 12.6% of women worldwide; its aetiology is complex and multifactorial and can be underpinned by uterine pathologies, systemic diseases and age. In addition, a new perspective has emerged on the role of the gut and vaginal microbiomes in reproductive health. Research shows that the administration of precisely selected probiotics, often in combination with prior antibiotic treatment, may facilitate the restoration of symbiotic microbiota to increase successful conception and assisted reproductive technology outcomes. However, clarity on this issue from fuller research is currently hampered by a lack of consistency and harmonization in clinical studies: various lactobacilli and bifidobacteria species have been delivered through both the oral and vaginal routes, in different dosages, for different treatment durations. This commentary explores the intricate relationship between the microbiota in the cervicovaginal area and gut of women, exploring their potential contribution to infertility. It highlights ongoing research on the use of probiotic formulations in improving pregnancy outcomes, critically examining the divergent findings in these studies, which complicate a conclusive assessment of the efficacy of these interventions.
科研通智能强力驱动
Strongly Powered by AbleSci AI